WASHINGTON , Aug. 24, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the European...
WASHINGTON , Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher,...
WASHINGTON , Aug. 5, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2026.
Barchart Research What to Expect from VNDA Earnings VNDA Generated August 4, 2026 Current Price $5.33 EPS Estimate $$-0.50 Consensus Rating Moderate Buy Average Move 8.65% Vanda Pharmaceuticals: The Tradipitant...
Barchart Research What to Expect from VNDA Earnings VNDA Generated July 29, 2026 Current Price $5.05 EPS Estimate $$-0.50 Consensus Rating Moderate Buy Average Move 8.65% Vanda's Pipeline Momentum Collides...
Conference Call and Webcast to Follow
WASHINGTON , July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA)...
WASHINGTON , July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention...
WASHINGTON , July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind,...